• James Jungkue Lee
  • CEO
  • Bridge Bio

Curriculum Vitae

Education

Master of Science, Department of Chemistry, Seoul National University (1993)

Professional Experience

Mr. James Jungkue Lee co-founded Bridge Biotherapeutics in 2015 and has served as CEO. Prior to Bridge, he founded Rexbio, specialized in discovery of monoclonal antibody for the treatment of pancreatic cancer. He co-founded CrystalGenomics in 2000 and had played key roles in financing and business development until 2007. He started industry career at LG Chemical Ltd (currently LG Life Sciences) 1993 after earning MS degree at Department of Chemistry, Seoul National University.

Research Interests

First-in-class drug development

Honors & Awards

Publications